MP70-15 INTRA-PROSTATIC PRX302 FOCAL THERAPY IN TREATING CLINICALLY SIGNIFICANT LOW-INTERMEDIATE PROSTATE CANCER: AN OPEN LABEL, PROOF-OF-CONCEPT STUDY | Zendy

AI Assistant Blog Pricing

MP70-15 INTRA-PROSTATIC PRX302 FOCAL THERAPY IN TREATING CLINICALLY SIGNIFICANT LOW-INTERMEDIATE PROSTATE CANCER: AN OPEN LABEL, PROOF-OF-CONCEPT STUDY

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.